Brief: FDA Grants Accelerated Approval For Padcev® (Enfortumab Vedotin-Ejfv) With Keytruda® (Pembrolizumab) For First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer

Seagen

03/04/2023 22:03

April 3 (Reuters) - Seagen Inc  SGEN.O :
    * FDA GRANTS ACCELERATED APPROVAL FOR PADCEV® (ENFORTUMAB
VEDOTIN-EJFV) WITH KEYTRUDA® (PEMBROLIZUMAB) FOR FIRST-LINE
TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
    * FDA GRANTS ACCELERATED APPROVAL FOR PADCEV® (ENFORTUMAB
VEDOTIN-EJFV) WITH KEYTRUDA® (PEMBROLIZUMAB) FOR FIRST-LINE
TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Source text for Eikon:  ID:nPn3wb65Pa 
Further company coverage:  SGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))